Dr. Edward V. Loftus JR., M.D.
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Years since graduation
- 38
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 183
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
MN license 35742 · AZ license 24999 · IA license MD-31755 · WI license 36565
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mayo Clinic Hospital Rochester Rochester, MN
- Mayo Clinic Health System - Albert Lea and Austin Albert Lea, MN
Medical groups
- Mayo Clinic (4,956 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 183
- Services billed
- 340
- Patients’ average age
- 69
| Service | Times | Patients |
|---|---|---|
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 79 | 79 |
| Established patient office or other outpatient visit, 30-39 minutes | 61 | 53 |
| Established patient office or other outpatient visit, 40-54 minutes | 39 | 35 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 34 | 34 |
| Biopsy of large bowel using a flexible endoscope | 32 | 32 |
| Established patient office or other outpatient visit, 20-29 minutes | 15 | 12 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 11 | 11 |
| New patient office or other outpatient visit, 45-59 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Stelara (ustekinumab) | 111 |
| Ciprofloxacin Hcl Other prescribers in Rochester, MN | 60 |
| Humira(Cf) Pen (adalimumab) Other prescribers in Rochester, MN | 46 |
| Azathioprine Other prescribers in Rochester, MN | 35 |
| Cimzia (2 Pack) (certolizumab pegol) | 35 |
| Omeprazole Other prescribers in Rochester, MN | 34 |
| Budesonide Dr (budesonide) Other prescribers in Rochester, MN | 33 |
| Mesalamine Other prescribers in Rochester, MN | 30 |
| Xifaxan (rifaximin) Other prescribers in Rochester, MN | 30 |
| Famotidine Other prescribers in Rochester, MN | 29 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 12 companies reported 35 payments worth $67,161 in total to this clinician.
| Takeda Pharmaceuticals U.S.A., Inc. | $29,606 |
|---|---|
| Janssen Global Services, LLC | $9,654 |
| Merck Sharp & Dohme LLC | $6,060 |
| Lilly USA, LLC | $5,850 |
| Genentech, Inc. | $5,836 |
| Janssen Biotech, Inc. | $3,686 |
| Eli Lilly and Company | $3,600 |
| Janssen Research & Development, LLC | $1,860 |
| Consulting Fee | $39,261 |
|---|---|
| Travel and Lodging | $21,009 |
| Compensation for services other than consulting (speaking, faculty) | $6,328 |
| Food and Beverage | $495 |
| Education | $68.49 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. Oct 29, 2025 | Travel and Lodging ENTYVIO · INTERNAL MEDICINE · travel to ROCHESTER, MN · in-kind | $19,888 |
| Janssen Global Services, LLC Sep 13, 2025 | Consulting Fee | $8,550 |
| Takeda Pharmaceuticals U.S.A., Inc. Oct 29, 2025 | Compensation for services other than consulting (speaking, faculty) ENTYVIO · INTERNAL MEDICINE | $6,328 |
| Merck Sharp & Dohme LLC May 26, 2025 | Consulting FeeCompany’s descriptionPayment made to Third Party Organization not to Physician. | $5,760 |
| Janssen Biotech, Inc. May 10, 2025 | Consulting Fee TREMFYA · Immunology | $3,600 |
| Genentech, Inc. Nov 18, 2025 | Consulting Fee | $3,421 |
| Takeda Pharmaceuticals U.S.A., Inc. Mar 20, 2025 | Consulting Fee | $3,390 |
| Lilly USA, LLC Feb 24, 2025 | Consulting Fee OMVOH · Immunology | $3,150 |
| Eli Lilly and Company Dec 11, 2025 | Consulting FeeCompany’s descriptionSERVICES TO SUPPORT RESEARCH RELATED ACTIVITIES | $2,925 |
| Lilly USA, LLC Feb 24, 2025 | Consulting Fee OMVOH · Immunology | $2,700 |
All 24 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Eli Lilly and Company Dec 18, 2025 | Consulting FeeCompany’s descriptionSERVICES TO SUPPORT RESEARCH RELATED ACTIVITIES | $675 |
| Eli Lilly and Company Dec 11, 2025 | Consulting FeeCompany’s descriptionSERVICES TO SUPPORT RESEARCH RELATED ACTIVITIES | $2,925 |
| Genentech, Inc. Nov 18, 2025 | Consulting Fee | $3,421 |
| Takeda Pharmaceuticals U.S.A., Inc. Oct 29, 2025 | Travel and Lodging ENTYVIO · INTERNAL MEDICINE · travel to ROCHESTER, MN · in-kind | $19,888 |
| Takeda Pharmaceuticals U.S.A., Inc. Oct 29, 2025 | Compensation for services other than consulting (speaking, faculty) ENTYVIO · INTERNAL MEDICINE | $6,328 |
| Janssen Global Services, LLC Sep 13, 2025 | Consulting Fee | $8,550 |
| Janssen Global Services, LLC Sep 13, 2025 | Travel and Lodging travel to JERSEY CITY, NJ · in-kind | $442 |
| Janssen Global Services, LLC Sep 13, 2025 | Travel and Lodging travel to JERSEY CITY, NJ · in-kind | $243 |
| Janssen Global Services, LLC Sep 13, 2025 | Travel and Lodging travel to JERSEY CITY, NJ | $108 |
| Janssen Global Services, LLC Sep 13, 2025 | Travel and Lodging travel to JERSEY CITY, NJ · in-kind | $45.53 |
| Janssen Global Services, LLC Sep 13, 2025 | Travel and Lodging travel to JERSEY CITY, NJ | $42.32 |
| Janssen Global Services, LLC Sep 12, 2025 | Travel and Lodging travel to JERSEY CITY, NJ · in-kind | $89.96 |
| AstraZeneca Pharmaceuticals LP Jul 29, 2025 | Education IMFINZI · Oncology · in-kind Company’s descriptionJournal Article | $68.49 |
| Janssen Research & Development, LLC Jun 16, 2025 | Consulting Fee TREMFYA · Immunology | $930 |
| Merck Sharp & Dohme LLC May 26, 2025 | Consulting FeeCompany’s descriptionPayment made to Third Party Organization not to Physician. | $5,760 |
| Merck Sharp & Dohme LLC May 19, 2025 | Travel and Lodging travel to San Diego, CA Company’s descriptionPayment made to Third Party Organization not to Physician. | $150 |
| Janssen Biotech, Inc. May 10, 2025 | Consulting Fee TREMFYA · Immunology | $3,600 |
| Celltrion USA Inc. May 4, 2025 | Consulting Fee ZYMFENTRA · GASTROENTEROLOGY | $815 |
| Janssen Research & Development, LLC Apr 1, 2025 | Consulting Fee TREMFYA · Immunology | $930 |
| Genentech, Inc. Mar 25, 2025 | Consulting Fee | $1,208 |
| Takeda Pharmaceuticals U.S.A., Inc. Mar 20, 2025 | Consulting Fee | $3,390 |
| Lilly USA, LLC Feb 24, 2025 | Consulting Fee OMVOH · Immunology | $3,150 |
| Lilly USA, LLC Feb 24, 2025 | Consulting Fee OMVOH · Immunology | $2,700 |
| Genentech, Inc. Feb 24, 2025 | Consulting Fee | $1,208 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 21 industry-funded studies in 2025, from 3 companies. The companies reported $491,842 in research payments for these studies, mostly to the institutions running them.
- A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.
AbbVie Inc. · Active, not recruiting · NCT06063967 - M14-430 - A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433
AbbVie Inc. - Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)
AbbVie Inc. · Active, not recruiting · NCT04524611 - A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
AbbVie Inc. · Active, not recruiting · NCT03345823 - A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)
AbbVie Inc. · Active, not recruiting · NCT03006068 - Vixarelimab ulcerative colitis study
Genentech, Inc. - A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
AbbVie Inc. · Active, not recruiting · NCT06880744 - A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis
AbbVie Inc. · Active, not recruiting · NCT03398135 - A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
AbbVie Inc. · Active, not recruiting · NCT03105102 - A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis
AbbVie Inc. · Active, not recruiting · NCT06257875
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.